EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer

Ken Onodera, Hirotsugu Notsuda, Sakiko Kumata, Tatsuaki Watanabe, Yui Watanabe, Takaya Suzuki, Takashi Hirama, Hisashi Oishi, Yoshinori Okada

Surgery Today · 2025

DOI: 10.1007/s00595-025-03070-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery Today, 2025. Verfasst von Ken Onodera und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Ja…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The expression of PD-L1 is linked to lung cancer severity; however, its prognostic value after resection is unclear. In this study, we investigated its role in resected lung cancers.

Methods

We analyzed 658 patients with stage pIA–IIIA NSCLC who underwent complete resection. We assessed the PD-L1 expression by stage and its link to cancer severity, focusing further on its prognostic impact in resected stage I cell lung cancer.

Results

The high expression of PD-L1 increased with disease progression (13.0% in IA to 36.2% in III). In stage I non-small cell lung cancer, elevated PD-L1 expression levels were more common in patients with serum CEA levels ≥ 5 (26.0%), SUVmax ≥ 5 (26.7%), and squamous cell carcinoma (41.5%). PD-L1-negative patients showed a better prognosis than PD-L1-positive patients, even with the use of immune checkpoint inhibitors following relapse (5-year OS: 94.3% vs. 83.2%, p < 0.01).

Conclusion

The expression of PD-L1 in lung cancer appears to be associated with oncological severity and may influence the prognosis of early-stage disease. Additionally, in early-stage lung cancer, immune checkpoint inhibitors may not fully compensate for the negative prognostic impact of the high expression of PD-L1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenLung NeoplasmsCarcinoma, Non-Small-Cell LungBiomarkers, TumorGene ExpressionHumansPrognosisNeoplasm StagingMaleFemaleMiddle AgedAgedSeverity of Illness IndexDisease ProgressionAdultAged, 80 and over

Stichwörter der Autor:innen

ExpressionLung cancerMalignancyNSCLCPD-L1

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. ken.onodera.c3@tohoku.ac.jp.
  • Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Zitieren

APA

Onodera, K., Notsuda, H., Kumata, S., Watanabe, T., Watanabe, Y., Suzuki, T., Hirama, T., Oishi, H., & Okada, Y. (2025). PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer. Surgery Today. https://doi.org/10.1007/s00595-025-03070-6

Vancouver

Onodera K, Notsuda H, Kumata S, Watanabe T, Watanabe Y, Suzuki T, et al. PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer. Surgery Today. 2025. doi:10.1007/s00595-025-03070-6

BibTeX
@article{Onodera2025,
  author = {Onodera, Ken and Notsuda, Hirotsugu and Kumata, Sakiko and Watanabe, Tatsuaki and Watanabe, Yui and Suzuki, Takaya and Hirama, Takashi and Oishi, Hisashi and Okada, Yoshinori},
  title = {PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer},
  journal = {Surgery Today},
  year = {2025},
  doi = {10.1007/s00595-025-03070-6}
}
Kostenlos starten →